Liposcience Inc (LPDX) financial statements (2022 and earlier)

Company profile

Business Address 2500 SUMNER BOULEVARD
RALEIGH, NC 27616
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
3/31/2013
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments39,99642,78945,05049,57451,57454,24655,047
Cash and cash equivalents39,99642,78945,05049,57451,57454,24655,047
Receivables3,8844,3525,8375,8216,5116,8497,098
Inventory, net of allowances, customer advances and progress billings199191188224212250185
Inventory199191188224212250185
Prepaid expense and other current assets8751,012
Other undisclosed current assets6971,0951,504972878  
Total current assets:44,77648,42752,57956,59159,17562,22063,342
Noncurrent Assets
Property, plant and equipment16,56416,33615,32813,95512,58012,12511,971
Intangible assets, net (including goodwill)753863891841764739692
Intangible assets, net (excluding goodwill)753863891841764739692
Restricted cash and investments5025025025025025011,504
Deferred costs47535964748392
Other noncurrent assets5335384563  
Prepaid expense and other noncurrent assets6856
Total noncurrent assets:17,91917,78916,81815,40713,98313,51614,315
TOTAL ASSETS:62,69566,21669,39771,99873,15875,73677,657
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,7381,4371,5732,0451,8074,6524,552
Accounts payable1,7381,4371,5732,0451,8071,1931,309
Accrued liabilities     3,4593,243
Debt3,9042,411  3,9042,411953
Due to related parties    3  
Other liabilities      1
Other undisclosed current liabilities3,8333,93919,10819,5603,818  
Total current liabilities:9,4757,78720,68121,6059,5317,0635,506
Noncurrent Liabilities
Long-term debt and lease obligation11,96113,437  11,88413,34914,781
Long-term debt, excluding current maturities11,96113,437  11,88413,34914,781
Liabilities, other than long-term debt2,5492,5772,6062,6352,6362,5362,518
Other liabilities2,5492,5772,6062,6352,6362,5362,518
Total noncurrent liabilities:14,51016,0142,6062,63514,52015,88517,299
Total liabilities:23,98523,80123,28724,24024,05122,94822,805
Stockholders' equity
Stockholders' equity attributable to parent38,71042,41546,11047,75849,10752,78854,852
Common stock15151515151515
Additional paid in capital109,582109,027108,666108,271107,004106,058105,678
Accumulated deficit(70,887)(66,627)(62,571)(60,528)(57,912)(53,285)(50,841)
Total stockholders' equity:38,71042,41546,11047,75849,10752,78854,852
TOTAL LIABILITIES AND EQUITY:62,69566,21669,39771,99873,15875,73677,657

Income statement (P&L) ($ in thousands)

9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
3/31/2013
Q1
Revenues
(Revenue, Net)
8,5629,04512,00812,71812,73813,31113,616
Cost of revenue
(Cost of Goods and Services Sold)
(2,272)(2,461)(2,614)(2,968)(2,808)(3,016)(3,250)
Other undisclosed gross profit   300200400400
Gross profit:6,2906,5849,39410,05010,13010,69510,766
Operating expenses(10,122)(10,209)(11,007)(12,224)(14,309)(12,690)(13,098)
Operating loss:(3,832)(3,625)(1,613)(2,174)(4,179)(1,995)(2,332)
Nonoperating income66529251914
Investment income, nonoperating66519272621
Other nonoperating income (expense)   10(2)(7)(7)
Interest and debt expense(434)(437)(435)(471)(473)(468)(530)
Net loss available to common stockholders, diluted:(4,260)(4,056)(2,043)(2,616)(4,627)(2,444)(2,848)

Comprehensive Income ($ in thousands)

9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
3/31/2013
Q1
Net loss:(4,260)(4,056)(2,043)(2,616)(4,627)(2,444)(2,848)
Comprehensive loss, net of tax, attributable to parent:(4,260)(4,056)(2,043)(2,616)(4,627)(2,444)(2,848)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: